Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

BioArctic AB (BRCTF) reports a surge in revenue and profit, driven by strategic alliances and expanding market presence, while addressing future challenges.

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's ...

Preparations are under way in our marketing organization for the joint launch, together with Eisai, of Leqembi in the Nordic countries. An important step in this process is ensuring that the ...

EMA’s reluctance in approving drugs for the condition underscores Europe’s prioritisation of long-term safety over rapid ...

Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, whereby the following resolutions were made. Adoption of the income statement ...

The test will initially be available at about 50 American research institutes and hospitals that specialise in Alzheimer’s ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...